The Advisors Asset Management Inc. Buys Shares of 6,175 Boston Scientific Corp. (BSX)

The Advisors Asset Management Inc. Buys Shares of 6,175 Boston Scientific Corp. (BSX)

Advisors Asset Management Inc. purchased a new position in shares of Boston Scientific Corp. (NYSE:BSX) during the second quarter, Holdings Channel reports. The fund purchased 6,175 shares of the company’s stock, valued at approximately $144,000.

Other hedge funds have also bought and sold shares of the company. Wellington Management Group LLP boosted its stake in Boston Scientific Corp. by 9.1% in the first quarter. Wellington Management Group LLP now owns 103,378,526 shares of the company’s stock worth $1,944,549,000 after buying an additional 8,643,058 shares in the last quarter. Bollard Group LLC boosted its stake in Boston Scientific Corp. by 1.5% in the second quarter. Bollard Group LLC now owns 33,797,061 shares of the company’s stock worth $789,837,000 after buying an additional 500,370 shares in the last quarter. Geode Capital Management LLC boosted its stake in Boston Scientific Corp. by 2.4% in the first quarter. Geode Capital Management LLC now owns 10,967,874 shares of the company’s stock worth $205,888,000 after buying an additional 253,069 shares in the last quarter. Boston Partners boosted its stake in Boston Scientific Corp. by 11.9% in the second quarter. Boston Partners now owns 8,618,996 shares of the company’s stock worth $201,426,000 after buying an additional 915,558 shares in the last quarter. Finally, Legal & General Group Plc boosted its stake in Boston Scientific Corp. by 0.6% in the first quarter. Legal & General Group Plc now owns 5,912,219 shares of the company’s stock worth $111,206,000 after buying an additional 34,936 shares in the last quarter. Institutional investors own 92.06% of the company’s stock.

Shares of Boston Scientific Corp. (NYSE:BSX) traded down 0.26% during mid-day trading on Friday, hitting $23.42. 1,624,747 shares of the stock traded hands. Boston Scientific Corp. has a 52 week low of $15.67 and a 52 week high of $24.79. The firm’s 50-day moving average is $23.79 and its 200-day moving average is $22.51. The stock’s market cap is $31.87 billion.

Boston Scientific Corp. (NYSE:BSX) last announced its quarterly earnings results on Thursday, July 28th. The company reported $0.27 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.27. The firm had revenue of $2.13 billion for the quarter, compared to the consensus estimate of $2.05 billion. Boston Scientific Corp. had a positive return on equity of 22.66% and a negative net margin of 4.34%. The company’s quarterly revenue was up 15.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.22 earnings per share. On average, analysts forecast that Boston Scientific Corp. will post ($0.02) earnings per share for the current year.

BSX has been the topic of a number of analyst reports. TheStreet cut Boston Scientific Corp. from a “buy” rating to a “hold” rating in a research note on Thursday, July 28th. Leerink Swann reaffirmed a “buy” rating on shares of Boston Scientific Corp. in a report on Friday, July 29th. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $26.00 price objective on shares of Boston Scientific Corp. in a report on Tuesday, June 21st. Zacks Investment Research lowered Boston Scientific Corp. from a “buy” rating to a “hold” rating in a report on Wednesday, August 31st. Finally, Wedbush raised their price objective on Boston Scientific Corp. from $23.00 to $25.00 and gave the stock a “neutral” rating in a report on Friday, July 29th. Five equities research analysts have rated the stock with a hold rating and twenty-two have given a buy rating to the company. Boston Scientific Corp. has a consensus rating of “Buy” and a consensus target price of $25.07.

In other news, EVP Timothy A. Pratt sold 24,000 shares of the company’s stock in a transaction on Monday, August 1st. The stock was sold at an average price of $24.46, for a total transaction of $587,040.00. Following the transaction, the executive vice president now directly owns 287,495 shares of the company’s stock, valued at $7,032,127.70. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP David A. Pierce sold 2,480 shares of the stock in a transaction dated Wednesday, July 20th. The shares were sold at an average price of $24.03, for a total value of $59,594.40. Following the completion of the transaction, the senior vice president now directly owns 28,080 shares in the company, valued at approximately $674,762.40. The disclosure for this sale can be found here. Insiders own 1.31% of the company’s stock.

Boston Scientific Corp. Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions (PI), Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation.

Related posts

Leave a Comment